Ocuphire Pharma, Inc. (OCUP)
NASDAQ: OCUP · IEX Real-Time Price · USD
1.850
+0.210 (12.80%)
At close: May 2, 2024, 4:00 PM
1.810
-0.040 (-2.16%)
Pre-market: May 3, 2024, 5:21 AM EDT
Ocuphire Pharma Revenue
In the year 2023, Ocuphire Pharma had annual revenue of $19.05M, a decrease of -52.20%. Revenue in the quarter ending December 31, 2023 was $1.69M, a -95.76% decrease year-over-year.
Revenue (ttm)
$19.05M
Revenue Growth
-52.20%
P/S Ratio
2.41
Revenue / Employee
$1,360,643
Employees
14
Market Cap
45.90M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
Dec 31, 2021 | 589.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 75.00K | - | - |
Dec 31, 2007 | 75.00K | - | - |
Dec 31, 2006 | 75.00K | - | - |
Dec 31, 2005 | 75.00K | - | - |
Dec 31, 2004 | 75.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
American Oncology Network | 1.28B |
Cara Therapeutics | 20.97M |
ReWalk Robotics | 13.85M |
Dyadic International | 2.90M |
Renalytix | 2.41M |
SAB Biotherapeutics | 2.24M |
OCUP News
- 10 days ago - Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting - GlobeNewsWire
- 21 days ago - First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery - GlobeNewsWire
- 4 weeks ago - Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris - GlobeNewsWire
- 7 weeks ago - Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Ocuphire Pharma to Present in the BIO CEO & Investor Conference - GlobeNewsWire
- 2 months ago - Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Ocuphire Pharma Strengthens Leadership Team with Key Appointments - GlobeNewsWire
- 3 months ago - Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference - GlobeNewsWire